

## Review

# Small molecules, big effects: the role of microRNAs in regulation of cardiomyocyte death

J Skommer<sup>1,3</sup>, I Rana<sup>1,3</sup>, FZ Marques<sup>1</sup>, W Zhu<sup>2</sup>, Z Du<sup>2</sup> and FJ Charchar<sup>\*1</sup>

MicroRNAs (miRNAs) are a class of small non-coding RNAs involved in posttranscriptional regulation of gene expression, and exerting regulatory roles in plethora of biological processes. In recent years, miRNAs have received increased attention for their crucial role in health and disease, including in cardiovascular disease. This review summarizes the role of miRNAs in regulation of cardiac cell death/cell survival pathways, including apoptosis, autophagy and necrosis. It is envisaged that these miRNAs may explain the mechanisms behind the pathogenesis of many cardiac diseases, and, most importantly, may provide new avenues for therapeutic intervention that will limit cardiomyocyte cell death before it irreversibly affects cardiac function. Through an in-depth literature analysis coupled with integrative bioinformatics (pathway and synergy analysis), we dissect here the landscape of complex relationships between the apoptosis-regulating miRNAs in the context of cardiomyocyte cell death (including regulation of autophagy–apoptosis cross talk), and examine the gaps in our current understanding that will guide future investigations.

*Cell Death and Disease* (2014) 5, e1325; doi:10.1038/cddis.2014.287; published online 17 July 2014

**Facts**

- There are altered cardiac microRNAs levels in various cardiovascular diseases states
- MicroRNAs can regulate cardiac cell proliferation, hypertrophy, death and cardiac fibrosis pathways.
- MicroRNAs have long biological half-lives, hence can be a good diagnostic marker of disease state

**Open Questions**

- What are the mechanisms leading to increase or decrease in cardiac microRNAs under pathological and physiological state?
- What are the mechanisms by which microRNAs contribute to cardiac pathological and physiological state?
- What are the cardiac microRNA changes associated with aging?
- How do microRNAs regulate the balance between pro-survival and death pathways in the heart?

Cell death processes are highly regulated in order to ensure proper tissue functioning and homeostasis. Loss of cardiomyocytes is an important factor in the pathogenesis of

conditions such as myocardial infarction (MI),<sup>1</sup> and occurs through a variety of cell death pathways, induction of which depends not only on the type of stress stimuli, but also on the intracellular biochemical and genetic makeup.<sup>2</sup> Most importantly, the converging regulatory network of cell death pathways is potentially amenable for control and therapeutic intervention.<sup>3</sup>

Over the last several years, efforts have been directed toward elucidating the exact regulatory mechanisms that govern cell death processes, including protein oligomerisation, protein conformational changes, transient protein–protein interactions and protein relocations (for example, Vela *et al.*<sup>4–8</sup>), as well as non-genetic cell-to-cell variability.<sup>9–12</sup> Recently, microRNAs (miRNAs) have emerged as an important, perhaps critical, regulatory factor when it comes to cell death signaling. This is not surprising considering that miRNAs, a class of small non-coding RNAs, posttranscriptionally regulate messenger RNAs by inhibiting their translation or promoting their degradation, and thus represent a new paradigm that regulates the expression of up to 50% of human genes.<sup>13,14</sup> According to the latest version of miRNA database miRBase 20.0, there are over 2500 known mature miRNAs in the human genome.<sup>15</sup>

Increasing evidence indicates that miRNAs are linked with many pathological conditions, and play important roles in cardiovascular homeostasis and in initiation and progression of disease states, such as hypertrophy and heart failure.<sup>16–18</sup>

<sup>1</sup>Robert HT Smith Chair in Cardiovascular Science, School of Health Sciences, Federation University Australia, Ballarat, Victoria 3350, Australia and <sup>2</sup>Institute of Clinical Pharmacology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China

\*Corresponding author: F Charchar, Robert HT Smith Chair in Cardiovascular Science, School of Health Sciences, Federation University Australia, PO Box 663, Ballarat, Victoria 3353, Australia. Tel: +61 3 5327 6098; Fax: +61 3 5327 9242; E-mail: federation.edu.au/charchar-lab

<sup>3</sup>These two authors contributed equally to this work.

**Abbreviations:** STEMI, ST-elevation myocardial infarction; MI, myocardial infarction; DAXX, death domain-associated protein; HIF1A, hypoxia inducible factor 1, alpha subunit; MFF, mitochondrial fission factor; HSP, heat shock protein; PC, progenitor cells; PKC, protein kinase C; PDCD4, programmed cell death 4; SIRT1, sirtuin 1; SNP, single-nucleotide polymorphism; FasL, Fas ligand

Received 14.3.14; revised 28.5.14; accepted 03.6.14; Edited by G Melino

Considering the role of cell death processes in cardiovascular disease (CVD) as well as the emerging role of miRNAs in regulating cardiac physiological and pathological states, we will focus our review on the role of miRNAs in regulating myocardial cell death processes.

### The World of miRNAs

Small non-coding RNA molecules of ~22–23 nucleotides in length, known as miRNAs, regulate the expression of protein-coding genes through sequence-specific recognition in the 3' or the 5' untranslated regions (UTRs) of mRNAs, thus regulating mRNA levels by posttranscriptional mechanisms.<sup>14,19</sup> Partial sequence complementarity between a miRNA and its target site in a specific mRNA is often sufficient for binding.<sup>20</sup> In animals, the binding to the 3'UTR lowers mRNA levels by preferentially decreasing the stability of the mRNA, thus increasing its degradation, or by repressing translation.<sup>14</sup> miRNAs were also described to bind to the promoter region in the 5'UTR of mRNAs.<sup>21,22</sup> The binding of miRNAs to 5'UTRs can either repress or, most likely, activate translation (reviewed by Da Sacco and Masotti<sup>19</sup> and Vasudevan<sup>23</sup>). Since no examples of this type of miRNA–mRNA interactions are known in CVD or cell death, this review will explore mechanisms involving miRNAs that bind to the 3'UTR of mRNAs only.

miRNA biogenesis has been extensively reviewed elsewhere.<sup>24–26</sup> Briefly, transcription of miRNA genes is usually performed by RNA polymerase (RNA Pol) II, or occasionally by RNA Pol III, resulting in a precursor miRNA, termed primary miRNA or pri-miRNA.<sup>26</sup> In the nucleus pri-miRNAs (~1000 bp) fold into hairpin structures, which act as a substrate for DGCR8 subunit of Drosha, a nuclear enzyme of the RNase III family, resulting in the cleavage of the pri-miRNA into a pre-miRNA (~60–70-bp long). The pre-miRNA is then exported to the cytoplasm, where Dicer, another enzyme of the RNase III family, processes the pre-miRNA to a ~20-bp double-stranded miRNA duplexes.<sup>24–26</sup> The miRNA duplexes associate with specific members of the Argonaute (Ago) family of proteins, and together form the core of the RNA-silencing complex (RISC), which mediates the posttranscriptional regulation of gene expression by utilizing the guide strand (miR) of the miRNA duplex.<sup>24–26</sup> There is now evidence that the second miRNA strand, often called passenger or minor miRNA (miR\*), before believed to be degraded, can also associate with Ago proteins and impact gene expression.<sup>27</sup>

Several algorithms are used for the discovery of miRNA–mRNA interactions (reviewed by Witkos *et al.*<sup>28</sup>), with computational predictions suggesting that a single miRNA can potentially regulate multiple mRNAs.<sup>20,28</sup> *In vitro* experimentation, however, is always necessary to validate the predicted targets as well as the role of miRNAs in regulation of cell signaling pathways and cellular phenotypes. Moreover, the general role of miRNAs in specific cellular or physiological processes can be examined by deleting or inhibiting miRNA-processing machinery. For instance, the cardiac-specific knockout of Dicer leads to rapidly progressive dilated cardiomyopathy, heart failure and postnatal lethality, emphasizing the importance of miRNAs for heart development and homeostasis.<sup>29–31</sup>

### Types of Cell Death


Cell death is a group of fundamental processes in both normal physiology and pathological states. The mammalian cell death network comprises of many distinct functional modules,<sup>32–34</sup> including apoptosis (also referred to as programmed cell death), macroautophagy (commonly referred to as autophagy, and more appropriately as cell death dependent on autophagy genes), necrosis and an inflammatory form of cell death referred to as pyroptosis.<sup>35</sup> Of these, apoptosis has been studied most extensively and its molecular framework is relatively well defined.<sup>36</sup> Often more than one process of cell death is induced, and the particular extracellular milieu, as well as genetic and biochemical context of the intracellular environment, will determine which pathway is ultimately responsible for cell demise. Because of this, blocking one pathway of cell death may not prevent the final outcome of cell loss, as other simultaneously induced pathways may take over the executioner's role. At the same time, genetic and pharmacological inhibitor studies can identify the culprit pathway among all the signaling induced by a particular stress cue. Thus, detailed knowledge of multiple pathways, their regulators and cross talks between them, is of paramount importance when it comes to interfering with cell death process for therapeutic purposes.

### Apoptotic Pathways in Cardiovascular Disease

The process of apoptosis is driven by a network of proteins connected to each other in an intricate manner, forming two main signaling pathways activated by a wide variety of stress signals that converge on mitochondria (the intrinsic pathway) or upon ligation of cell surface death receptors (the extrinsic pathway) (Figure 1). Caspase-9 activation by mitochondrial pathway and caspase-8 activation by extrinsic pathway lead to activation of the executioner caspases, such as caspase-3 or -7 which then directly degrade the proteome and commit cells to death (Figure 1).

Cytochrome *c* released from damaged mitochondria act as a trigger for the activation of the mitochondrial pathway. The mitochondrial pathway of apoptosis is heavily regulated by multiple proteins acting upstream and downstream of the mitochondria, determining the efficiency of apoptotic cell death (Figure 1). Control over the integrity of mitochondrial outer membrane is executed by the proteins of the B-cell lymphoma 2 (Bcl-2) family, divided into three subfamilies: anti-apoptotic (for example, Bcl-2, Bcl-XL, Mcl-1, Bcl-w), pro-apoptotic effectors (Bax and Bak) and BH3-only proteins (for example, Bid, Puma, Bim, Bad and so on), which form a complex network of interactions (discussed in more detail in several reviews, including<sup>6,37–39</sup>). Downstream of mitochondria, activation of caspases is also heavily regulated, first by the low-probability event of apoptosome formation and second by inhibitor of apoptosis (IAP) proteins such as XIAP (Figure 1).

In the extrinsic pathway of apoptosis, the initial stress signal comes from the binding of a death domain-containing receptor, located at the plasma membrane, to its cognate ligand (for example, Fas ligand (FasL) or tumor necrosis factor- $\alpha$  (TNF- $\alpha$ )).<sup>40</sup> Upon binding, the receptor promotes the



**Figure 1** A simplified schematic representation of the extrinsic and the intrinsic (mitochondrial) pathways of apoptosis and necroptosis. The mitochondrial (intrinsic) pathway of cell death is regulated both upstream (Bcl-2 proteins) and downstream (e.g., IAP proteins) of mitochondria. In response to stress, mitochondria undergo permeabilisation of the outer mitochondrial membrane (MOMP), which leads to a release of a number of pro-apoptotic factors such as cytochrome c, AIF or EndoG. The extrinsic pathway of apoptosis is activated via a complex signal transduction from the plasma membrane, whereby the death receptors (e.g., Fas, TNFR) bind their cognate ligands (e.g., FasL, TNF), oligomerize, activate their intracellular death domains and recruit a number of receptor-associated proteins such as RIP1 or TRADD. The multiprotein complex then recruits the initiator pro-caspase-8 leading to its activation. Active caspase-8 propagates the apoptotic signal either by direct activation of executioner caspases, or by cleaving a BH3 protein Bid which then leads to MOMP. In addition, components of the protein machinery that regulates the extrinsic pathway of apoptosis are also involved in regulation of necrosis. The figure also demonstrates apoptosis regulatory microRNA and their target genes in apoptotic pathways

formation of the death-inducing complex (DISC) that activates caspase-8 (Figure 1). In some cell types, caspase-8 cleaves the BH3 protein Bid, forming truncated Bid (tBid) and ultimately inducing the mitochondrial outer membrane permeabilisation. Thus, in some contexts, there is a cross talk between the extrinsic and the intrinsic pathway of apoptosis.

Cardiomyocytes undergo apoptosis in response to a plethora of stimuli including hypoxia (especially followed by reoxygenation), acidosis, oxidative stress, glucose deprivation and metabolic restriction,  $\beta_1$ -adrenergic agonists, stretch, angiotensin II (Ang II), TNF- $\alpha$ , Fas L and anthracyclines as reviewed in.<sup>41</sup> Even though it is often postulated that necrosis is the main pathway responsible for cardiomyocyte death following MI, several observations in human, rabbit, rat and mice hearts indicate that apoptotic cell death contributes to the overall cardiomyocyte loss following MI, particularly during subacute and chronic stages of infarction and after reperfusion,<sup>42–47</sup> as well as in end-stage cardiomyopathy and in terminally failing human myocardium.<sup>48,49</sup> Cardiomyocyte apoptosis has also been shown to contribute to left ventricle dysfunction following cardiac surgery,<sup>50</sup> particularly after retrograde cardioplegia.<sup>51</sup> Moreover, inhibition of post-ischemic cardiomyocyte apoptosis emerges as an effective therapeutic avenue to improve diastolic heart function after ischemia.<sup>52</sup>

Studies indicate the relevance of both the mitochondrial and the extrinsic pathway of apoptosis in cardiac pathologies. The mitochondrial pathway of apoptosis is activated following

myocardial ischemia-reperfusion injury,<sup>53</sup> whereas TNF- $\alpha$ , a trigger of the death receptor pathway, is rapidly released from resident mast cells and macrophages in response to myocardial ischemia,<sup>54</sup> and can also be released from cardiomyocytes.<sup>55</sup> Overexpression of FasL was also shown to increase cardiomyocyte apoptosis *in vitro* and *in vivo*.<sup>56</sup> The fact that multiple cell death pathways are detectable and occur side-by-side is not surprising, and is a common phenomenon observed in contexts ranging from retrovirus-induced immunosuppression<sup>57</sup> to chemotherapy-induced cancer cell death.<sup>58–60</sup> Therefore, it is well recognized that activation of a particular cell death pathway does not constitute sufficient evidence to support its physiological importance in the pathological process, and instead needs to be supported by prevention of cell loss using pathway-specific pharmacological and/or genetic inhibition. In this regard, conflicting results have been published. For example, it was observed that Fas-deficient *lpr* mice exhibit reduced infarcts and diminished apoptosis after myocardial ischemia-reperfusion (I/R) injury, both *ex vivo* and *in vivo*,<sup>56,61</sup> whereas in transgenic mouse lines with cardiomyocyte-specific overexpression of Bcl-2 or dominant-negative Fas-associated death domain (FADD)<sup>53</sup> only inhibition of the mitochondrial pathway provided a significant decrease in the size of infarction following coronary artery ligation. Of note, in the latter study, there was still a substantial decrease in the number of apoptotic (TUNEL positive) cardiomyocytes in FADD dominant-negative mouse line, suggesting that forms of cell death other than apoptosis

were contributing to the infarct size. In addition, in *lpr* mice Fas-deficiency is not limited to cardiomyocytes. Therefore, more studies in models where apoptosis contributes significantly to the infarct, and where it is blocked specifically in cardiomyocytes, are needed to provide more evidence as to the role of specific apoptotic pathways.

### miRNAs that Regulate Cardiovascular Sensitivity to Apoptosis

The role of miRNAs in regulating the expression of anti- and pro-apoptotic genes and regulation of cardiomyocyte and endothelial cell survival is well documented (Table 1). miRNAs appear to regulate cardiomyocyte apoptosis through multiple mechanisms. When it comes to the mitochondrial pathway of apoptosis, several miRNAs target the *BCL2* gene, including miR-1, miR-15 family and miR-21, whereas *PUMA* and *BIM*, which encode for the pro-apoptotic BH3 proteins, are targeted by miR-149 and miR-214 (as well as miR-24), respectively (Table 1). In addition, mitochondrial fission machinery is regulated by miR-30 family, which targets the *TP53* gene encoding for p53 protein which in turn regulates the expression of mitochondrial fission protein dynamin-related protein-1 (*Drp1*), and by miR-761, which targets a gene encoding for mitochondrial fission factor (*Mff*) (Table 1).<sup>62</sup> Of note, a particular recent study suggests that *Mff* is responsible for recruiting *Drp1* to the foci at the outer mitochondrial membrane.<sup>63</sup> Downstream of mitochondria, the expression of *CASP9*, which encodes for the initiator caspase-9, is regulated by miR-133a, whereas *CASP3*, which encodes for the executioner caspase-3, is regulated by miR-378 (Table 1). In addition, miR-21 regulates genes involved in the death receptor pathway of apoptosis, including death domain-associated protein gene (*DAXX*) and *FASLG*, which encode for death receptor-associated protein and Fas L, respectively (Table 1).

Genes encoding proteins that control ROS signaling are also enriched among the targets of apoptosis-regulating cardiac miRNAs. In particular, three miRNAs, that is, miR-34a, miR-195 and miR-199a, target *SIRT1* (Table 1), which encodes for a founding member of a family of NAD-dependent deacetylases called sirtuins. When expressed at low levels, *SIRT1* has been reported to protect cardiomyocytes from oxidative stress and apoptosis, and stimulation of Sirt1 protein mimics ischemic preconditioning and protects heart from I/R injury (reviewed in greater detail by Sundaresan *et al.*<sup>64</sup> and Yamamoto and Sadoshima<sup>65</sup>). Other ROS signaling genes targeted by cardiac miRNAs include *TXN* (encoding for thioredoxin) and *SOD* (encoding for superoxide dismutase). Interestingly, a study on mice with cardiac-specific overexpression of Sirt1 revealed that it upregulates the expression of both superoxide dismutase and thioredoxin 1.<sup>66</sup> Considering that multiple miRNAs associated with apoptotic regulation in cardiomyocytes impinge on the network of SIRT1-ROS signaling, while some other miRNAs affect ROS-induced signaling pathways, such as changes in free calcium (for example, miR-145<sup>67</sup>), more research is required to delineate the exact mechanism and causal role of miRNAs in maintaining cardiac redox homeostasis as well as the cell death regulatory role of redox-sensitive miRNAs.

Consistent with tissue-specific functions, many miRNAs have distinct biological effects depending on the cell type. For example, inhibition of miR-24 has been reported to promote cardiomyocyte apoptosis while decreasing the survival of endothelial cells.<sup>68</sup> Considering this, more work is needed to investigate the apoptosis-regulating effects of miR-17-92 cluster, which appears to be expressed at high level in the heart and has been extensively reported to exert anti-apoptotic effects in tumor cells.<sup>69</sup> Only few studies, however, have been reported so far with regards to the cardiac apoptosis regulation by this miRNA cluster (see Table 1). Of note, the variability in the role of miRNAs is observed not only between the cell types, but also between cellular processes, particularly as they relate to the effect on tissue functioning. For example, in cardiac myocytes, the signaling pathways that regulate hypertrophy impinge also on the balance between cell survival and cell death,<sup>70</sup> and many miRNAs may be involved in regulation of this delicate balance.


The striking abundance of miRNAs involved in the regulation of apoptosis in cardiomyocytes suggests the possibility of an extensive overlap of regulatory functions and effects on intracellular signaling. Such synergy between miRNAs has been recently investigated using receiver operating characteristic (ROC) analysis, which indicated that miR-21 scores high for its synergistic effects. Of particular interest, the synergistic effect of miR-21 and miR-1 was detected, and functionally validated in the context of regulation of myocardial apoptosis, cardiac hypertrophy and fibrosis.<sup>71</sup> Here, we have used the integrated parameter synergy score calculations (Figure 2), based upon the experimentally validated and confidently predicted miRNA-target interaction data obtained from miRsel<sup>72</sup> and TargetsScanHuman 6.2, to calculate the synergy scores for the miRNAs linked to cardiomyocyte apoptosis (Figure 3). In total, we identified 35 synergistic (synergy score of more than 2.0) pair-wise combinations of miRNAs. This finding confirms that the synergistic action of these miRNAs on cardiomyocyte apoptosis should not be ignored. As observed before,<sup>71</sup> miR-21 was most commonly involved in synergistic interactions ( $n = 10$ ) (Figure 3a), with particularly strong synergy between miR-21 and miR-1 (Figure 3b), followed by two miR-15 family members miR-15a and miR-16 (each of them synergized with nine other miRNAs). In comparison, several miRNAs were not involved in synergistic interaction, as indicated by the synergy score  $< 2.0$ . These miRNAs include miR-133a, miR-149, miR-19b, miR-210, miR-214, miR-30, miR-320, miR-378, miR-499 and miR-761 (example given in Figure 3c). Overall, this analysis indicates that there is a selective synergism among endogenous miRNAs in regulating complex biological processes such as apoptosis.

In addition, we used the Ingenuity Pathway Analysis (IPA) to determine network of connections between the identified apoptosis-regulating miRNAs of reported relevance to cardiovascular disease (Figure 4). We observed that many miRNAs are regulated through each other either directly or indirectly, and many are indirectly regulated by the same signaling molecules, for example, beta estradiol (Figure 4). In this context, it is interesting to note that to the best of our knowledge, no experimental studies have been published so far on estradiol-mediated regulation of cardiac miRNAs,



**Table 1** Summary of miRNAs linked to apoptotic regulation in cardiomyocytes

miRNAs	Relevance to CVD	Targets relevant to apoptosis	Refs
miR-1	Serum expression upregulated in human AMI and in patients after open-heart surgery with cardiopulmonary bypass Overexpression enhances and inhibition attenuates apoptosis and infarct area after cardiac I/R injury in mice Overexpression inhibits apoptosis in a rat model of cardiac hypertrophy induced by pressure overload Ischemic post-conditioning upregulates miR-1 and inhibits cardiomyocyte apoptosis in rats Inhibition <i>in vitro</i> in cardiomyocytes reduces H <sub>2</sub> O <sub>2</sub> -induced and high-glucose-induced apoptosis Upregulation has pro-apoptotic effect in H9c2 cells exposed to oxidative stress miR-1 transfected ES cells protect host myocardium from MI-induced apoptosis overexpression enhances the angiogenic differentiation of human cardiomyocyte PC Upregulated in rat cardiomyocytes exposed to high glucose Downregulated in response to Tanshinone IIA	<i>PRKCE</i> (protein kinase C) <i>HSPD1</i> (HSP60) <i>BCL2</i>	147–159
miR-15 family	Upregulated in response to MI Silencing <i>in vitro</i> renders cardiomyocytes resistant to hypoxia-induced cell death Regulates angiogenic activity of endothelial cells	<i>BCL2</i>	160–163
miR-133a	Upregulation of miR-133a following ischemic post-conditioning miR-133a mimic attenuated IR-induced apoptosis in rats Anti-apoptotic effect in H9c2 cells exposed to oxidative stress Elevated levels of miR-133a in patients with ST-elevation myocardial infarction (STEMI) linked to more severe injury	<i>CASP9</i>	155,156,164,165
miR-17-92 cluster	Increased expression in Tanshinone IIA-treated hypoxic neonatal cardiomyocytes Overexpression of the cluster results in lethal cardiomyopathy Expression decreases in aging mice hearts miR-20a is upregulated in mechanically stretched neonatal rat cardiomyocytes and exerts anti-apoptotic effect		166–169
miR-21	Overexpression of miR-19b inhibits apoptosis in P19 cells Myocardial upregulation of miR-21 reduces MI size and apoptotic rate by increasing Bcl-2 levels Expression declines in cardiac myocytes upon exposure to hypoxia, and increases after ischemic preconditioning Overexpression diminishes murine coxsackievirus B3-induced myocarditis Overexpression in transgenic mouse heart results in smaller infarct following ischemia Expression elevated in circulating endothelial progenitor cells from diabetic patients and protective from high-glucose-induced apoptosis	<i>BCL2</i> <i>FASLG</i> (FASL) <i>PDCD4</i> <i>ANXA2</i> <i>SOD2</i> <i>TXNDAXX</i>	170–176
miR-24	Expressed in cardiac valve endothelium, where it regulates the development of AV valve Expression lower in peri-infarct tissue in mouse model of MI Inhibition induces cardiomyocyte apoptosis <i>In vivo</i> overexpression inhibits cardiomyocyte apoptosis and attenuates infarct size Inhibition enhances EC survival	<i>BIM</i>	68,177
miR-30	Inhibits mitochondrial fission and apoptosis in cardiomyocytes	<i>TP53</i>	178
miR-150	Upregulated in cardiac myocytes treated with H <sub>2</sub> O <sub>2</sub> Silencing protects from H <sub>2</sub> O <sub>2</sub> -induced apoptosis Dysregulated in human MI	<i>MYB</i> (c-myb)	147,179
miR-210	Upregulated in hypoxic cardiomyocytes Overexpression reduces cell death in response to oxidative stress Deregulated in human MI	?	147,180
miR-199a	Downregulated to undetectable levels during cardiac ischemia <i>in vitro</i> and <i>in vivo</i> Overexpression inhibits hypoxia-induced expression of several pro-apoptotic genes (e.g. <i>CASP3</i> and <i>CASP9</i> )	<i>HIF1A</i> <i>SIRT1</i>	181
miR-320	Downregulated in murine hearts following I/R Overexpression enhanced cardiomyocyte apoptosis	<i>HSPB6</i> ( <i>Hsp20</i> )	182
miR-149	Overexpression decreases apoptotic sensitivity G-allele of A > G SNP in pre-miR-149 decreases production of miR-149 and influences cardiac function in mouse model of MI	<i>BBC3</i> ( <i>PUMA</i> )	183
miR-761	Inhibits mitochondrial fission Knockdown diminished H <sub>2</sub> O <sub>2</sub> -induced and I/R-induced cardiomyocyte apoptosis and infarct size in mice	<i>MTOR</i>	62
miR-499	Inhibits cardiomyocyte apoptosis	<i>PPP3CA</i> , <i>PPP3CB</i>	184
miR-214	Protects cardiomyocytes from H <sub>2</sub> O <sub>2</sub> -induced apoptosis <i>in vitro</i> Genetic deletion in mice increases cardiac apoptosis	<i>PTEN</i> <i>BIM</i>	185,186
miR-145	Circulating levels reduced in patients with coronary artery disease Ameliorates ROS-induced apoptosis in cardiomyocytes	<i>CAMK2G</i>	67,187
miR-378	Downregulated in a rat model of myocardial ischemia Overexpression in H9c2 cardiomyocytes reduces apoptosis and necrosis	<i>CASP3</i>	188
miR-195	Inhibition increases H <sub>2</sub> O <sub>2</sub> -induced apoptosis Inhibition leads to decreased ROS production and apoptosis in palmitate-treated mouse cardiomyocytes	<i>SIRT1</i>	189
miR-34a	Expression increases with aging (in mice) Inhibition reduces cardiomyocyte apoptosis Levels higher in endothelial progenitor cells from coronary artery disease patients Regulates SIRT1 expression in endothelial progenitor cells and contributes to endothelial senescence	<i>SIRT1</i> <i>PNUTS</i>	125,190,191



**Figure 2** A graphic representation for quantitative assessment of miRNA synergy. (a) Targeting more common genes creates synergy between two miRNAs. (b) Denser functional association between proteins encoded by individual miRNA-target genes makes two miRNAs more likely to act synergistically

despite a well-recognized cardioprotective (via an anti-apoptotic mechanism) function of estrogen.<sup>73–86</sup>

### Autophagy, a Double-Edged Sword in Cardiovascular Disease

Autophagy is an evolutionarily conserved mechanism of cellular self-digestion in which long-lived proteins and entire organelles are degraded through delivery to lysosomes (Figure 5). It is characterized by the formation of autophagosomes, cellular structures that encapsulate cytoplasmic cargoes. Autophagosomes ultimately fuse with lysosomes to form autolysosomes in which the contents are degraded into their constituent parts and delivered back into the cytosol for further biocatalysis or to be utilized in biosynthetic pathways.

It is well documented that basal levels of autophagy, operating in the majority, if not all, cells, serve to maintain homeostasis by removing misfolded or aggregated proteins, and by clearance of damaged organelles such as mitochondria and endoplasmic reticulum.<sup>87,88</sup> Both the rate of autophagy and the selection of cargoes destined for degradation can, however, change in response to specific external and internal cues. In this context, excessive autophagy, induced in response to stress signals, can have dual effects, acting either to maintain cell survival (for example, by providing essential energy for sustaining physiological function during the times of catabolic defects) or contributing to cell death (e.g., by diminishing cell volume or providing energy for the execution of apoptosis).

Defects in the process of autophagy have been implicated in numerous human diseases, including cardiovascular diseases such as hypertrophy and heart failure (reviewed in Marzetti *et al.*<sup>89–92</sup>). Moreover, induction of autophagy by perioperative ischemia/reperfusion has been observed.<sup>93</sup>

Considering that autophagy can potentially exert both pro- and anti-survival function, it is not surprising that its role in cardiovascular disease remains relatively poorly understood, with some studies pointing toward its beneficial effects,<sup>94–99</sup> while others suggest its detrimental role.<sup>100</sup> Nevertheless, the preponderance of evidence supports the notion of beneficial role for autophagy in the heart.

### MiRNAs and Cardiovascular Autophagy: The Causality Dilemma


The role of miRNAs in regulation of autophagy was first suggested in 2009, when *BECN1*, a gene encoding for Beclin 1 which is an important factor controlling vesicle nucleation (see Figure 5), was shown to be posttranscriptionally regulated by miR-30a.<sup>101</sup> Since then, multiple miRNAs have been linked to the autophagic pathway and have been associated with disease states, including cardiac pathologies (Table 2). In addition, there are several miRNAs that have been reported to modulate autophagy in other tissues, and have also known roles in cardiac function. For example, in hematopoietic cells, miR-17 has been shown to regulate the expression of SQSTM1 (p62), an ubiquitin-binding protein and regulator of autophagy-mediated protein degradation,<sup>102</sup> and the expression of *ATG7* in glioblastoma cells.<sup>103</sup> It also appears to modulate cardiac remodeling following MI.<sup>104</sup> Whether miR-17 regulates cardiac autophagy remains to be investigated.

We conducted pathway analysis of miRNAs linked to cardiac autophagy, using the Ingenuity Pathway Analysis (IPA) software (Ingenuity Systems, Qiagen, Redwood City, CA, USA), and discovered two main nodes of interaction, that is p53 and STAT3 (signal transducer and activator of transcription 3) (Figure 6). Interestingly, both p53 and STAT3 are known as critical regulators of autophagy. Specifically, STAT3 inhibitors or genetic ablation stimulate autophagic flux,<sup>105,106</sup> and reduced levels of STAT3 are reported in patients with end-stage heart failure.<sup>107,108</sup> Moreover, the activation of STAT3 by angiotensin (Ang)II-induced Janus-activated kinase 2 (JAK-2) is impaired in failing human cardiomyocytes.<sup>109</sup> With regards to p53, its inhibition is cardioprotective against ischemic injury, and an increase in autophagic flux has been observed in p53 (–/–) heart under ischemic conditions.<sup>110</sup> This effect is suggested to occur through the p53-TIGAR axis,<sup>110</sup> with TIGAR (TP53-induced glycolysis and apoptosis regulator) being involved in regulation of the glycolysis and pentose phosphate pathway, ROS-levels, and inhibition of apoptosis and autophagy.<sup>111,112</sup> The p53-TIGAR axis has also been specifically shown to regulate cellular energy homeostasis and cell death in cardiomyocytes under ischemic stress.<sup>113</sup> There is a need for more detailed studies on the role of miRNAs in regulation of such complex signaling pathways, and their role in the context of myocardial cell death.

### At the Crossroad of Apoptosis and Autophagy

It is a hackneyed expression that simultaneous induction of multiple cell signaling pathways occurs in biological systems, but it is nonetheless true, even in the context of concurrent induction of cell death and cell survival pathways. Concomitant





**Figure 3.** miRNA synergy in cardiac apoptosis. (a) Synergy score calculation for random combinations of validated miRNAs that are involved in cardiac apoptosis. Synergy scores of more than 2.0 are highlighted as thick red-dash lines. (b) Network location of apoptosis-related proteins encoded by target genes of miR-1 (red nodes), miR-21 (green nodes) and both (yellow nodes). (c) Network location of apoptosis-related proteins encoded by target genes of miR-1 (red nodes), miR-30 (blue nodes) and both (purple nodes). Synergistic apoptosis regulation should be expected for the pair of miR-1 and miR-21 instead of miR-1 and miR-30, due to more common target genes and denser functional association between gene-encoded products. Synergy score<sub>miR-1:miR-21</sub> = 3.23; Synergy score<sub>miR-1:miR-30</sub> = 1.13; Box shows the network core area





(via p53 and the activation of FoxO transcription factor family members).<sup>127,128</sup> Thus, miR-34a-mediated regulation of *PNUTS* and *SIRT1* expression in cardiac cells could contribute to changes in apoptosis–autophagy switch in response to stress and during cardiac recovery and remodeling.


Interestingly, increased levels of the miRNA miR-34a appear to be also associated with telomere shortening, with overexpression of *PNUTS* in human cardiomyocytes leading to telomere attrition.<sup>125</sup> Telomere shortening is a well-known

trigger of cellular senescence and has also been associated with several CVDs, including MI and the onset and progression of arterial hypertension.<sup>129</sup> Contrary to cell death, senescence is a process of irreversible cell cycle arrest which allows cells to remain viable and metabolically active for a long time (at least in *in vitro* cell culture). Cells undergoing senescence exhibit several phenotypic changes, including enhanced autophagy, the role of which, according to a recent study, is to process cytoplasmic chromatin fragments budded off nuclei.<sup>130</sup> Another miR-34a target gene, *SIRT1*, is also known to influence certain aspects of vascular ageing, including senescence.<sup>131,132</sup> This suggests another mechanism for miRNA-regulated cardiomyocyte autophagy involving senescence signaling pathways.

### miRNAs in Cardiovascular Necrosis

Necrosis is a type of cell death which is morphologically characterized by increase of cell volume, dilation of organelles, rupture of the plasma membrane and subsequent loss of intracellular contents.<sup>34</sup> For a long time, necrosis was considered to be a passive, accidental and unregulated form of cell death, and as such was sharply contrasted against heavily regulated and tightly orchestrated apoptosis. This view has changed over the last few years, with increasing number of reports describing the regulatory network that governs necrotic cell death (reviewed in Henriquez *et al.*<sup>133</sup> and Wu *et al.*<sup>134</sup>). Many authors suggest that myocardial ischemia results predominantly in necrotic cell death,<sup>135</sup> due to depletion of ATP, increased calcium load, acidosis and severe oxidative stress, with apoptotic cell death playing a role following reperfusion. Accordingly, inhibitors of necrotic cell death appear to be effective at reducing myocardial cell death and infarct size in animal models.<sup>136</sup> In addition, myocardial necrosis is relatively common among infants who die as a result of congenital heart disease, perinatal asphyxia, sepsis or coronary artery abnormalities.<sup>137</sup>

So far, only limited evidence has been gathered on the role of miRNAs in regulation of cardiac necrosis. A recent study has reported that miR-874 inhibits cardiomyocyte necrosis, *in vitro* as well as in animal model of MI, via downregulation of




**Figure 5** Key steps in the autophagic pathway. The process is initiated by the formation of autophagosomes, double-membrane vesicles that engulf fractions of the cytosol. Autophagosomes undergo a step-wise maturation associated with expansion and completion of the sequestering vesicle, which is regulated by many ATG proteins, particularly Beclin-1 and two ubiquitin-like conjugation systems Atg12-Atg5-Atg16L and Atg8(LC3)-PE. Autophagosomes then fuse with lysosomes to form single-membrane autolysosomes. In this process, autophagosomes acquire hydrolytic enzymes and are able to degrade the sequestered material. Recycling of the basic components, such as amino or fatty acids, helps the cell to maintain homeostasis

**Table 2** Autophagy-modulating miRNAs with relevance to CVD

miRNAs	Relevance to CVD	Targets relevant to autophagy	Function	Refs
miR-30	Downregulated in a model of cardiac hypertrophy and by angiotensin II Circulating miR-30 elevated in patients with left-ventricular hypertrophy	<i>BECN1</i>	Vesicle nucleation	192
miR-204	Reduces cardiomyocytes autophagy in response to hypoxia-reoxygenation Concomitant downregulation of miR-204 and induction of autophagy following cardiac ischemia-reperfusion in rats Downregulated in pulmonary arterial smooth muscle cells from patients with PAH	<i>MAP1LC3A</i>	Vesicle maturation and fusion with the lysosome	193,194 195
miRNA-212/132	Impaired autophagy in starved cardiomyocytes	<i>FOXO3 PTEN</i>	Pro-autophagic transcription factor	196
miR-21	Induced cardiac hypertrophy Cell treatment with anti-miR-21 induced autophagy Not yet investigated with regards to cardiomyocyte autophagy	<i>BECN1 MAP1LC3A PIK3C3 (VPS34)</i>		197



**Figure 6** Ingenuity network analysis of miRNAs identified as regulators of apoptosis in cardiomyocytes (and miR-21)



**Figure 7** MiR-34a as potential regulator of the cross talk between autophagic and apoptotic signaling in cardiac cells. PNUTS is a PTEN-associated protein that sequesters PTEN to the nucleus<sup>127</sup>

the expression of caspase-8,<sup>138</sup> which normally serves not only as an element of the death receptor pathway, but also as a pro-survival regulator that suppresses necrosis.<sup>139</sup> Apart from caspase-8, other components of death receptor pathway, for example, receptor interacting protein 1 (RIP1), are also involved in regulation of necrosis (see Figure 1). In this regard, overexpression of miR-155 was reported to attenuate necrotic cell death in cardiomyocyte progenitor cells exposed to hydrogen peroxide.<sup>140</sup> Considering the continuum and interdependence of cell death pathways, as well as the clinical importance of necrosis in conditions such as myocardial infarction, more work is needed to decipher the exact role of miRNAs in necrotic cell death.

Necroptosis is a specialized pathway of programmed necrosis (Figure 1), targeting the kinase RIP1 involved in extrinsic pathway of apoptosis.<sup>141</sup> Necroptosis shares characteristics of both necrosis and apoptosis.<sup>142,143</sup> A study on mice model has showing that a bolus dose of necroptosis inhibitor, necrostatin-1, in mice at the time of coronary

reperfusion dramatically reduced infarct size after I/R njury.<sup>144</sup> These results indicates important role of necroptosis in regulation of cardiac cell death. Involvement of necroptosis in myocardia injury after Mi and in other cardiovascular conditions has not been investigated in detail. Further investigation on this pathway may hold promise for finding further clinical targets for treating heart diseases.

**Can miRNAs Regulate Cell-to-Cell Variability in Cardiac Cell Death?**

The performance of the apoptotic network determines the individual cell's probability to die, which, when assessed over a large population of cells, can be translated into the percent of cell death at a given time point. The apoptotic pathway consists of many processes that are stochastic in nature, that is, occur with certain probability rather than in a deterministic fashion. These processes include protein translocation (e.g., translocation of Bax from the cytosol to mitochondria) or formation of multiprotein complexes (e.g., the apoptosome). The architecture of the network includes also positive and negative feedback loops, which may buffer or enhance the inherent noise in the apoptotic signaling. Therefore, the net balance between the amount of pro- and anti-apoptotic proteins, the spatial and temporal availability of protein partners for interaction and functioning of the feedback loops are all critical for determining the performance of the apoptotic network and thus the threshold of stress signal required for successful execution of cell death at the level of cell population.

Gene expression is subject to stochastic variability even among the cells with the same genotype and environment.<sup>145</sup> The inherent stochastic nature of transcriptional regulation affects cell ability to control gene expression levels in response to extracellular stimuli, including stress cues. In the context of cell death, such cell-to-cell variability translates to dramatic differences in the time between exposure to stress and the execution of cell demise.<sup>9,12</sup> The differences in kinetics of cell death are particularly pronounced when critical events involve small numbers of molecules, for example, apoptosome formation. Importantly, for many genes, the noise in the expression pattern increases as their expression decreases. As miRNAs affect cell homeostasis by regulating gene expression, it is conceivable that they inherently contribute to the cell-to-cell variability in cell signaling as well as to the robustness of cell phenotypes and responses to stimuli, including pro-apoptotic stimuli. This field of research remains, as of now, largely unexplored, with only a few attempts to analyze the stochastic properties of regulatory clusters involving miRNAs.<sup>146</sup> It is, nevertheless, and exciting avenue with potentially far-reaching implications when it comes to regulation of cardiomyocyte cell death, particularly in the contexts of a delayed and slow-progressing response outcome of which can be substantially affected by changes in cell-to-cell variability. This line of research will require not only knowledge of the effects of specific miRNAs on oscillations in gene expression patters but also stochastic version of deterministic models employed traditionally to study cell signaling pathways.

## Summary and Future Outlook

Through an in-depth analysis of the current evidence linking miRNAs with regulation of cardiomyocyte cell death pathways, and the understanding of regulatory nodes (including cross talks between the pathways and non-genetic regulation of cell-to-cell variability in cell death), we have identified several new research avenues, pursuit of which may be of pivotal importance to our understanding of regulatory circuits that govern survival and death of cardiomyocytes. These avenues include the role of redox-sensitive miRNAs, the effects of beta estradiol in regulation of miRNAs expression and action in the heart, the role of miRNAs in regulating the balance between pro-survival and death pathways as well as cell-to-cell variability in timing and extent of phenotypic response. The emerging systems-biology approach to studying the functional synergy between cardiac miRNAs in the context of cell death pathways should be extended to incorporate more extended network of signaling pathways, including ROS signaling. This should help to elucidate the full impact of miRNAs on gene expression networks and biological pathways. In the context of these observations, there is a need for investigation of aging-associated cardiac miRNAs that affect cell death pathways. Further studies are also required to understand mechanisms responsible for reported cardiac microRNA changes during myocardial infarction, chronic kidney disease, hypertension, diabetes and other cardiac pathological conditions of cardiac death. Analysis of the fine balance between the apoptotic and hypertrophic roles of cardiac miRNAs will contribute to the understanding of the complex interactions between multiple cardiac-specific miRNAs in aging. We envisage that all these studies will form a solid framework for development of future therapies for the treatment of cardiovascular diseases, based on anti-miR/miRNA overexpression approaches.

## Conflict of Interest

The authors declare no conflict of interest.

- Orogo AM, Gustafsson AB. Cell death in the myocardium: my heart won't go on. *IUBMB Life* 2013; **65**: 651–656.
- Konstantinidis K, Whelan RS, Kitsis RN. Mechanisms of cell death in heart disease. *Arterioscler Thromb Vasc Biol* 2012; **32**: 1552–1562.
- Reeve JL, Duffy AM, O'Brien T, Samali A. Don't lose heart—therapeutic value of apoptosis prevention in the treatment of cardiovascular disease. *J Cell Mol Med* 2005; **9**: 609–622.
- Vela L, Gonzalo O, Naval J, Marzo I. Direct interaction of Bax and Bak proteins with Bcl-2 homology domain 3 (BH3)-only proteins in living cells revealed by fluorescence complementation. *J Biol Chem* 2013; **288**: 4935–4946.
- Dusmann H, Rehm M, Concannon CG, Anguissola S, Wurstle M, Kacmar S *et al*. Single-cell quantification of Bax activation and mathematical modelling suggest pore formation on minimal mitochondrial Bax accumulation. *Cell Death Differ* 2010; **17**: 278–290.
- Chipuk JE, Moldoveanu T, Llambi F, Parsons MJ, Green DR. The BCL-2 family reunion. *Mol Cell* 2010; **37**: 299–310.
- Ow YP, Green DR, Hao Z, Mak TW. Cytochrome c: functions beyond respiration. *Nat Rev Mol Cell Biol* 2008; **9**: 532–542.
- Mace PD, Riedl SJ. Molecular cell death platforms and assemblies. *Curr Opin Cell Biol* 2010; **22**: 828–836.
- Spencer SL, Gaudet S, Albeck JG, Burke JM, Sorger PK. Non-genetic origins of cell-to-cell variability in TRAIL-induced apoptosis. *Nature* 2009; **459**: 428–432.
- Skommer J, Raychaudhuri S, Wlodkovic D. Timing is everything: stochastic origins of cell-to-cell variability in cancer cell death. *Front Biosci (Landmark Ed)* 2011; **16**: 307–314.
- Skommer J, Brittain T, Raychaudhuri S. Bcl-2 inhibits apoptosis by increasing the time-to-death and intrinsic cell-to-cell variations in the mitochondrial pathway of cell death. *Apoptosis* 2010; **15**: 1223–1233.
- Gaudet S, Spencer SL, Chen WW, Sorger PK. Exploring the contextual sensitivity of factors that determine cell-to-cell variability in receptor-mediated apoptosis. *PLoS Comput Biol* 2012; **8**: e1002482.
- Ohtani K, Dimmeler S. Control of cardiovascular differentiation by microRNAs. *Basic Res Cardiol* 2011; **106**: 5–11.
- Huntzinger E, Izaurralde E. Gene silencing by microRNAs: contributions of translational repression and mRNA decay. *Nat Rev Genet* 2011; **12**: 99–110.
- Kozomara A, Griffiths-Jones S. miRBase: integrating microRNA annotation and deep-sequencing data. *Nucleic Acids Res* 2011; **39**(Database issue): D152–D157.
- Leite-Moreira AM, Lourenco AP, Falcao-Pires I, Leite-Moreira AF. Pivotal role of microRNAs in cardiac physiology and heart failure. *Drug Discov Today* 2013; **18**: 1243–1249.
- Kumarswamy R, Thum T. Non-coding RNAs in cardiac remodeling and heart failure. *Circ Res* 2013; **113**: 676–689.
- Ono K, Kuwabara Y, Han J. MicroRNAs and cardiovascular diseases. *FEBS J* 2011; **278**: 1619–1633.
- Da Sacco L, Masotti A. Recent insights and novel bioinformatics tools to understand the role of microRNAs binding to 5' untranslated region. *Int J Mol Sci* 2012; **14**: 480–495.
- Pasquinelli AE. MicroRNAs and their targets: recognition, regulation and an emerging reciprocal relationship. *Nat Rev Genet* 2012; **13**: 271–282.
- Lytle JR, Yario TA, Steitz JA. Target mRNAs are repressed as efficiently by microRNA-binding sites in the 5' UTR as in the 3' UTR. *Proc Natl Acad Sci USA* 2007; **104**: 9667–9672.
- Orom UA, Nielsen FC, Lund AH. MicroRNA-10a binds the 5'UTR of ribosomal protein mRNAs and enhances their translation. *Mol Cell* 2008; **30**: 460–471.
- Vasudevan S. Posttranscriptional upregulation by microRNAs. *Wiley Interdiscip Rev RNA* 2012; **3**: 311–330.
- Berezikov E. Evolution of microRNA diversity and regulation in animals. *Nat Rev Genet* 2011; **12**: 846–860.
- Bernardo BC, Charchar FJ, Lin RC, McMullen JR. A microRNA guide for clinicians and basic scientists: background and experimental techniques. *Heart Lung Circ* 2012; **21**: 131–142.
- Graves P, Zeng Y. Biogenesis of mammalian microRNAs: a global view. *Genomics Proteomics Bioinformatics* 2012; **10**: 239–245.
- Bhayani MK, Calin GA, Lai SY. Functional relevance of miRNA sequences in human disease. *Mutat Res* 2012; **731**: 14–19.
- Witkos TM, Koscianska E, Krzyzosiak WJ. Practical aspects of microRNA target prediction. *Curr Mol Med* 2011; **11**: 93–109.
- Saxena A, Tabin CJ. miRNA-processing enzyme Dicer is necessary for cardiac outflow tract alignment and chamber septation. *Proc Natl Acad Sci USA* 2010; **107**: 87–91.
- da Costa Martins PA, Bourajaj M, Gladka M, Kortland M, van Oort RJ, Pinto YM *et al*. Conditional dicer gene deletion in the postnatal myocardium provokes spontaneous cardiac remodeling. *Circulation* 2008; **118**: 1567–1576.
- Chen JF, Murchison EP, Tang R, Callis TE, Tatsuguchi M, Deng Z *et al*. Targeted deletion of Dicer in the heart leads to dilated cardiomyopathy and heart failure. *Proc Natl Acad Sci USA* 2008; **105**: 2111–2116.
- Leist M, Jaattela M. Four deaths and a funeral: from caspases to alternative mechanisms. *Nat Rev Mol Cell Biol* 2001; **2**: 589–598.
- Meier P, Vousden KH. Lucifer's labyrinth—ten years of path finding in cell death. *Mol Cell* 2007; **28**: 746–754.
- Kroemer G, Galluzzi L, Vandenabeele P, Abrams J, Alnemri ES, Baehrecke EH *et al*. Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009. *Cell Death Differ* 2009; **16**: 3–11.
- Bergsbaken T, Fink SL, Cookson BT. Pyroptosis: host cell death and inflammation. *Nat Rev Microbiol* 2009; **7**: 99–109.
- Daniel NN, Korsmeyer SJ. Cell death: critical control points. *Cell* 2004; **116**: 205–219.
- Skommer J, Wlodkovic D, Deptala A. Larger than life: mitochondria and the Bcl-2 family. *Leuk Res* 2007; **31**: 277–286.
- Daniel NN. BCL-2 family proteins: critical checkpoints of apoptotic cell death. *Clin Cancer Res* 2007; **13**: 7254–7263.
- Cory S, Adams JM. The Bcl2 family: regulators of the cellular life-or-death switch. *Nat Rev Cancer* 2002; **2**: 647–656.
- Gonzalvez F, Ashkenazi A. New insights into apoptosis signaling by Apo2L/TRAIL. *Oncogene* 2010; **29**: 4752–4765.
- Crow MT, Mani K, Nam YJ, Kitsis RN. The mitochondrial death pathway and cardiac myocyte apoptosis. *Circ Res* 2004; **95**: 957–970.
- Takemura G, Fujiwara H. Role of apoptosis in remodeling after myocardial infarction. *Pharmacol Ther* 2004; **104**: 1–16.
- Gottlieb RA, Burleson KO, Kloner RA, Babior BM, Engler RL. Reperfusion injury induces apoptosis in rabbit cardiomyocytes. *J Clin Invest* 1994; **94**: 1621–1628.
- Fliiss H, Gatteringer D. Apoptosis in ischemic and reperfused rat myocardium. *Circ Res* 1996; **79**: 949–956.
- Freude B, Masters TN, Robicsek F, Fokin A, Kostin S, Zimmermann R *et al*. Apoptosis is initiated by myocardial ischemia and executed during reperfusion. *J Mol Cell Cardiol* 2000; **32**: 197–208.
- Wang XL, Liu HR, Tao L, Liang F, Yan L, Zhao RR *et al*. Role of iNOS-derived reactive nitrogen species and resultant nitrate stress in leukocytes-induced cardiomyocyte apoptosis after myocardial ischemia/reperfusion. *Apoptosis* 2007; **12**: 1209–1217.



47. Lee Y, Gustafsson AB. Role of apoptosis in cardiovascular disease. *Apoptosis* 2009; **14**: 536–548.
48. Narula J, Pandey P, Arbustini E, Haider N, Narula N, Kolodgie FD *et al*. Apoptosis in heart failure: release of cytochrome c from mitochondria and activation of caspase-3 in human cardiomyopathy. *Proc Natl Acad Sci USA* 1999; **96**: 8144–8149.
49. Scheubel RJ, Bartling B, Simm A, Silber RE, Drogaris K, Darmer D *et al*. Apoptotic pathway activation from mitochondria and death receptors without caspase-3 cleavage in failing human myocardium: fragile balance of myocyte survival? *J Am Coll Cardiol* 2002; **39**: 481–488.
50. Malmberg M, Parkka J, Vahasilta T, Saraste A, Laitio T, Kiss J *et al*. Cardiomyocyte apoptosis after cardioplegic ischemia: comparison to unprotected regional ischemia-reperfusion. *Eur Surg Res* 2011; **46**: 19–25.
51. Vahasilta T, Malmberg M, Saraste A, Koskenvuo JW, Parkka JP, Valtonen M *et al*. Cardiomyocyte apoptosis after antegrade and retrograde cardioplegia during aortic valve surgery. *Ann Thorac Surg* 2011; **92**: 1351–1357.
52. Roy N, Friehs I, Cowan DB, Zurakowski D, McGowan FX, del Nido PJ. Dopamine induces postischemic cardiomyocyte apoptosis *in vivo*: an effect ameliorated by propofol. *Ann Thorac Surg* 2006; **82**: 2192–2199.
53. Kristen AV, Ackermann K, Buss S, Lehmann L, Schnabel PA, Haunzetter A *et al*. Inhibition of apoptosis by the intrinsic but not the extrinsic apoptotic pathway in myocardial ischemia-reperfusion. *Cardiovasc Pathol* 2013; **22**: 280–286.
54. Gilles S, Zahler S, Welsch U, Sommerhoff CP, Becker BF. Release of TNF-alpha during myocardial reperfusion depends on oxidative stress and is prevented by mast cell stabilizers. *Cardiovasc Res* 2003; **60**: 608–616.
55. Dorge H, Schulz R, Belosjorow S, Post H, van de Sand A, Konietzka I *et al*. Coronary microembolization: the role of TNF-alpha in contractile dysfunction. *J Mol Cell Cardiol* 2002; **34**: 51–62.
56. Lee P, Sata M, Lefer DJ, Factor SM, Walsh K, Kitsis RN. Fas pathway is a critical mediator of cardiac myocyte death and MI during ischemia-reperfusion *in vivo*. *Am J Physiol Heart Circ Physiol* 2003; **284**: H456–H463.
57. Chien H, Dix RD. Evidence for multiple cell death pathways during development of experimental cytomegalovirus retinitis in mice with retrovirus-induced immunosuppression: apoptosis, necroptosis, and pyroptosis. *J Virol* 2012; **86**: 10961–10978.
58. Goc A, Kochuparambil ST, Al-Husein B, Al-Azayzih A, Mohammad S, Somanath PR. Simultaneous modulation of the intrinsic and extrinsic pathways by simvastatin in mediating prostate cancer cell apoptosis. *BMC Cancer* 2012; **12**: 409.
59. Rosato RR, Almenara JA, Dai Y, Grant S. Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells. *Mol Cancer Ther* 2003; **2**: 1273–1284.
60. Lin CC, Yang JS, Chen JT, Fan S, Yu FS, Yang JL *et al*. Berberine induces apoptosis in human HSC-3 oral cancer cells via simultaneous activation of the death receptor-mediated and mitochondrial pathway. *Anticancer Res* 2007; **27**: 3371–3378.
61. Jeremias I, Kupatt C, Martin-Villalba A, Habazettl H, Schenkel J, Boekstegers P *et al*. Involvement of CD95/Apo1/Fas in cell death after myocardial ischemia. *Circulation* 2000; **102**: 915–920.
62. Long B, Wang K, Li N, Murtaza I, Xiao JY, Fan YY *et al*. miR-761 regulates the mitochondrial network by targeting mitochondrial fission factor. *Free Radic Biol Med* 2013; **65C**: 371–379.
63. Otera H, Wang C, Cleland MM, Setoguchi K, Yokota S, Youle RJ *et al*. Mff is an essential factor for mitochondrial recruitment of Drp1 during mitochondrial fission in mammalian cells. *J Cell Biol* 2010; **191**: 1141–1158.
64. Sundaresan NR, Pillai VB, Gupta MP. Emerging roles of SIRT1 deacetylase in regulating cardiomyocyte survival and hypertrophy. *J Mol Cell Cardiol* 2011; **51**: 614–618.
65. Yamamoto T, Sadoshima J. Protection of the heart against ischemia/reperfusion by silent information regulator 1. *Trends Cardiovasc Med* 2011; **21**: 27–32.
66. Hsu CP, Zhai P, Yamamoto T, Maejima Y, Matsushima S, Hariharan N *et al*. Silent information regulator 1 protects the heart from ischemia/reperfusion. *Circulation* 2010; **122**: 2170–2182.
67. Cha MJ, Jang JK, Ham O, Song BW, Lee SY, Lee CY *et al*. MicroRNA-145 suppresses ROS-induced Ca<sup>2+</sup> overload of cardiomyocytes by targeting CaMKII $\delta$ . *Biochem Biophys Res Commun* 2013; **435**: 720–726.
68. Meloni M, Marchetti M, Garner K, Littlejohns B, Sala-Newby G, Xenophontos N *et al*. Local inhibition of microRNA-24 improves reparative angiogenesis and left ventricle remodeling and function in mice with myocardial infarction. *Mol Ther* 2013; **21**: 1390–1402.
69. Zhou M, Cai J, Tang Y, Zhao Q. MiR-17-92 cluster is a novel regulatory gene of cardiac ischemic/reperfusion injury. *Med Hypotheses* 2013; **81**: 108–110.
70. van Empel VP, De Windt LJ. Myocyte hypertrophy and apoptosis: a balancing act. *Cardiovasc Res* 2004; **63**: 487–499.
71. Zhu W, Zhao Y, Xu Y, Sun Y, Wang Z, Yuan W *et al*. Dissection of protein interactomics highlights MicroRNA synergy. *PLoS One* 2013; **8**: e63342.
72. Naeem H, Kuffner R, Csaba G, Zimmer R. miRSEL: automated extraction of associations between microRNAs and genes from the biomedical literature. *BMC Bioinformatics* 2010; **11**: 135.
73. Zhai P, Eurell TE, Cooke PS, Lubahn DB, Gross DR. Myocardial ischemia-reperfusion injury in estrogen receptor-alpha knockout and wild-type mice. *Am J Physiol Heart Circ Physiol* 2000; **278**: H1640–H1647.
74. Pelzer T, Schumann M, Neumann M, deJager T, Stimpel M, Serfling E *et al*. 17beta-estradiol prevents programmed cell death in cardiac myocytes. *Biochem Biophys Res Commun* 2000; **268**: 192–200.
75. Gabel SA, Walker VR, London RE, Steenbergen C, Korach KS, Murphy E. Estrogen receptor beta mediates gender differences in ischemia/reperfusion injury. *J Mol Cell Cardiol* 2005; **38**: 289–297.
76. Shen T, Yang C, Ding L, Zhu Y, Ruan Y, Cheng H *et al*. Tbx20 functions as an important regulator of estrogen-mediated cardiomyocyte protection during oxidative stress. *Int J Cardiol* 2013; **168**: 3704–3714.
77. Knowlton AA, Lee AR. Estrogen and the cardiovascular system. *Pharmacol Ther* 2012; **135**: 54–70.
78. Puzianowska-Kuznicka M. ESR1 in myocardial infarction. *Clin Chim Acta* 2012; **413**: 81–87.
79. Cao J, Zhu T, Lu L, Geng L, Wang L, Zhang Q *et al*. Estrogen induces cardioprotection in male C57BL/6J mice after acute myocardial infarction via decreased activity of matrix metalloproteinase-9 and increased Akt-Bcl-2 anti-apoptotic signaling. *Int J Mol Med* 2011; **28**: 231–237.
80. Voss MR, Stallone JN, Li M, Cornelussen RN, Knuefermann P, Knowlton AA. Gender differences in the expression of heat shock proteins: the effect of estrogen. *Am J Physiol Heart Circ Physiol* 2003; **285**: H687–H692.
81. Kam KW, Qi JS, Chen M, Wong TM. Estrogen reduces cardiac injury and expression of beta1-adrenoceptor upon ischemic insult in the rat heart. *J Pharmacol Exp Ther* 2004; **309**: 8–15.
82. Wang M, Crisostomo P, Wairiuko GM, Meldrum DR. Estrogen receptor-alpha mediates acute myocardial protection in females. *Am J Physiol Heart Circ Physiol* 2006; **290**: H2204–H2209.
83. Wang M, Crisostomo PR, Markel T, Wang Y, Lillemo KD, Meldrum DR. Estrogen receptor beta mediates acute myocardial protection following ischemia. *Surgery* 2008; **144**: 233–238.
84. Liou CM, Yang AL, Kuo CH, Tin H, Huang CY, Lee SD. Effects of 17beta-estradiol on cardiac apoptosis in ovariectomized rats. *Cell Biochem Funct* 2010; **28**: 521–528.
85. Liu H, Pedram A, Kim JK. Oestrogen prevents cardiomyocyte apoptosis by suppressing p38alpha-mediated activation of p53 and by down-regulating p53 inhibition on p38beta. *Cardiovasc Res* 2011; **89**: 119–128.
86. Kim JK, Pedram A, Razandi M, Levin ER. Estrogen prevents cardiomyocyte apoptosis through inhibition of reactive oxygen species and differential regulation of p38 kinase isoforms. *J Biol Chem* 2006; **281**: 6760–6767.
87. Glick D, Barth S, Macleod KF. Autophagy: cellular and molecular mechanisms. *J Pathol* 2010; **221**: 3–12.
88. Kubli DA, Gustafsson AB. Mitochondria and mitophagy: the yin and yang of cell death control. *Circ Res* 2012; **111**: 1208–1221.
89. Marzetti E, Csiszar A, Dutta D, Balagopal G, Calvani R, Leeuwenburgh C. Role of mitochondrial dysfunction and altered autophagy in cardiovascular aging and disease: from mechanisms to therapeutics. *Am J Physiol Heart Circ Physiol* 2013; **305**: H459–H476.
90. Dutta D, Calvani R, Bernabei R, Leeuwenburgh C, Marzetti E. Contribution of impaired mitochondrial autophagy to cardiac aging: mechanisms and therapeutic opportunities. *Circ Res* 2012; **110**: 1125–1138.
91. Gottlieb RA, Mentzer RM Jr. Autophagy: an affair of the heart. *Heart Fail Rev* 2013; **18**: 575–584.
92. Nishida K, Kyoji S, Yamaguchi O, Sadoshima J, Otsu K. The role of autophagy in the heart. *Cell Death Differ* 2009; **16**: 31–38.
93. Singh KK, Yanagawa B, Quan A, Wang R, Garg A, Khan R *et al*. Autophagy gene fingerprint in human ischemia and reperfusion. *J Thorac Cardiovasc Surg* 2013; **147**: 1065–1072.
94. Dutta D, Xu J, Kim JS, Dunn WA Jr, Leeuwenburgh C. Upregulated autophagy protects cardiomyocytes from oxidative stress-induced toxicity. *Autophagy* 2013; **9**: 328–344.
95. Kanamori H, Takemura G, Goto K, Maruyama R, Ono K, Nagao K *et al*. Autophagy limits acute myocardial infarction induced by permanent coronary artery occlusion. *Am J Physiol Heart Circ Physiol* 2011; **300**: H2261–H2271.
96. Taneike M, Yamaguchi O, Nakai A, Hikoso S, Takeda T, Mizote I *et al*. Inhibition of autophagy in the heart induces age-related cardiomyopathy. *Autophagy* 2010; **6**: 600–606.
97. Takemura G, Kanamori H, Goto K, Maruyama R, Tsujimoto A, Fujiwara H *et al*. Autophagy maintains cardiac function in the starved adult. *Autophagy* 2009; **5**: 1034–1036.
98. Tannous P, Zhu H, Johnstone JL, Shelton JM, Rajasekaran NS, Benjamin IJ *et al*. Autophagy is an adaptive response in desmin-related cardiomyopathy. *Proc Natl Acad Sci USA* 2008; **105**: 9745–9750.
99. Nakai A, Yamaguchi O, Takeda T, Higuchi Y, Hikoso S, Taniike M *et al*. The role of autophagy in cardiomyocytes in the basal state and in response to hemodynamic stress. *Nat Med* 2007; **13**: 619–624.
100. Zhao Y, Xue T, Yang X, Zhu H, Ding X, Lou L *et al*. Autophagy plays an important role in sunlitinib-mediated cell death in H9c2 cardiac muscle cells. *Toxicol Appl Pharmacol* 2010; **248**: 20–27.
101. Zhu H, Wu H, Liu X, Li B, Chen Y, Ren X *et al*. Regulation of autophagy by a beclin 1-targeted microRNA, miR-30a, in cancer cells. *Autophagy* 2009; **5**: 816–823.

102. Meenhuis A, van Veelen PA, de Looper H, van Boxtel N, van den Berge IJ, Sun SM *et al*. MiR-17/20/93/106 promote hematopoietic cell expansion by targeting sequestosome 1-regulated pathways in mice. *Blood* 2011; **118**: 916–925.
103. Comincini S, Allavena G, Palumbo S, Morini M, Durando F, Angeletti F *et al*. microRNA-17 regulates the expression of ATG7 and modulates the autophagy process, improving the sensitivity to temozolomide and low-dose ionizing radiation treatments in human glioblastoma cells. *Cancer Biol Ther* 2013; **14**: 574–586.
104. Li SH, Guo J, Wu J, Sun Z, Han M, Shan SW *et al*. miR-17 targets tissue inhibitor of metalloproteinase 1 and 2 to modulate cardiac matrix remodeling. *FASEB J* 2013; **27**: 4254–4265.
105. Shen S, Niso-Santano M, Adjemian S, Takehara T, Malik SA, Minoux H *et al*. Cytoplasmic STAT3 represses autophagy by inhibiting PKR activity. *Mol Cell* 2012; **48**: 667–680.
106. Elschami M, Scherr M, Philippens B, Gerardy-Schahn R. Reduction of STAT3 expression induces mitochondrial dysfunction and autophagy in cardiac HL-1 cells. *Eur J Cell Biol* 2013; **92**: 21–29.
107. Podewski EK, Hilfiker-Kleiner D, Hilfiker A, Morawietz H, Lichtenberg A, Wollert KC *et al*. Alterations in Janus kinase (JAK)-signal transducers and activators of transcription (STAT) signaling in patients with end-stage dilated cardiomyopathy. *Circulation* 2003; **107**: 798–802.
108. Boengler K, Buechert A, Heinen Y, Roeskes C, Hilfiker-Kleiner D, Heusch G *et al*. Cardioprotection by ischemic postconditioning is lost in aged and STAT3-deficient mice. *Circ Res* 2008; **102**: 131–135.
109. Cambi GE, Lucchese G, Djekong MM, Modesti A, Fiaschi T, Faggian G *et al*. Impaired JAK2-induced activation of STAT3 in failing human myocytes. *Mol Biosyst* 2012; **8**: 2351–2359.
110. Hoshino A, Matoba S, Iwai-Kanai E, Nakamura H, Kimata M, Nakaoka M *et al*. p53-TIGAR axis attenuates mitophagy to exacerbate cardiac damage after ischemia. *J Mol Cell Cardiol* 2012; **52**: 175–184.
111. Bensaad K, Cheung EC, Vousden KH. Modulation of intracellular ROS levels by TIGAR controls autophagy. *EMBO J* 2009; **28**: 3015–3026.
112. Bensaad K, Tsuruta A, Selak MA, Vidal MN, Nakano K, Bartrons R *et al*. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. *Cell* 2006; **126**: 107–120.
113. Kimata M, Matoba S, Iwai-Kanai E, Nakamura H, Hoshino A, Nakaoka M *et al*. p53 and TIGAR regulate cardiac myocyte energy homeostasis under hypoxic stress. *Am J Physiol Heart Circ Physiol* 2010; **299**: H1908–H1916.
114. Giansanti V, Torriglia A, Scovassi AI. Conversation between apoptosis and autophagy: 'Is it your turn or mine?'. *Apoptosis* 2011; **16**: 321–333.
115. Nishida K, Yamaguchi O, Otsu K. Crosstalk between autophagy and apoptosis in heart disease. *Circ Res* 2008; **103**: 343–351.
116. Marquez RT, Xu L. Bcl-2:Beclin 1 complex: multiple mechanisms regulating autophagy/apoptosis toggle switch. *Am J Cancer Res* 2012; **2**: 214–221.
117. Luo S, Rubinsztein DC. BCL2L1/BIM: a novel molecular link between autophagy and apoptosis. *Autophagy* 2013; **9**: 104–105.
118. Luo S, Garcia-Arencibia M, Zhao R, Puri C, Toh PP, Sadiq O *et al*. Bim inhibits autophagy by recruiting Beclin 1 to microtubules. *Mol Cell* 2012; **47**: 359–370.
119. Wirawan E, Vande Walle L, Kerse K, Cornelis S, Claeuwaert S, Vanoverberghe I *et al*. Caspase-mediated cleavage of Beclin-1 inactivates Beclin-1-induced autophagy and enhances apoptosis by promoting the release of proapoptotic factors from mitochondria. *Cell Death Dis* 2010; **1**: e18.
120. Li H, Wang P, Sun Q, Ding WX, Yin XM, Sobol RW *et al*. Following cytochrome c release, autophagy is inhibited during chemotherapy-induced apoptosis by caspase 8-mediated cleavage of Beclin 1. *Cancer Res* 2011; **71**: 3625–3634.
121. Yousefi S, Perozzo R, Schmid I, Ziemiecki A, Schaffner T, Scapozza L *et al*. Calpain-mediated cleavage of Atg5 switches autophagy to apoptosis. *Nat Cell Biol* 2006; **8**: 1124–1132.
122. Yin X, Cao L, Kang R, Yang M, Wang Z, Peng Y *et al*. UV irradiation resistance-associated gene suppresses apoptosis by interfering with BAX activation. *EMBO Rep* 2011; **12**: 727–734.
123. Rubinstein AD, Eisenstein M, Ber Y, Bialik S, Kimchi A. The autophagy protein Atg12 associates with antiapoptotic Bcl-2 family members to promote mitochondrial apoptosis. *Mol Cell* 2011; **44**: 698–709.
124. Pyo JO, Jang MH, Kwon YK, Lee HJ, Jun JI, Woo HN *et al*. Essential roles of Atg5 and FADD in autophagic cell death: dissection of autophagic cell death into vacuole formation and cell death. *J Biol Chem* 2005; **280**: 20722–20729.
125. Boon RA, Iekushi K, Lechner S, Seeger T, Fischer A, Heydt S *et al*. MicroRNA-34a regulates cardiac ageing and function. *Nature* 2013; **495**: 107–110.
126. Kavela S, Shinde SR, Ratheesh R, Viswakalyan K, Bashyam MD, Gowrishankar S *et al*. PNUMS functions as a proto-oncogene by sequestering PTEN. *Cancer Res* 2013; **73**: 205–214.
127. Ng F, Tang BL. Sirtuins' modulation of autophagy. *J Cell Physiol* 2013; **228**: 2262–2270.
128. Salminen A, Kaamiranta K. SIRT1: regulation of longevity via autophagy. *Cell Signal* 2009; **21**: 1356–1360.
129. Fyhrius F, Saijonmaa O. Telomere length and cardiovascular aging. *Ann Med* 2012; **44**(Suppl 1): S138–S142.
130. Ivanov A, Pawlikowski J, Manoharan I, van Tuyn J, Nelson DM, Rai TS *et al*. Lysosome-mediated processing of chromatin in senescence. *J Cell Biol* 2013; **202**: 129–143.
131. Wang F, Chen HZ, Lv X, Liu DP. SIRT1 as a novel potential treatment target for vascular aging and age-related vascular diseases. *Curr Mol Med* 2013; **13**: 155–164.
132. Ota H, Eto M, Ogawa S, Iijima K, Akishita M, Ouchi Y. SIRT1/eNOS axis as a potential target against vascular senescence, dysfunction and atherosclerosis. *J Atheroscler Thromb* 2010; **17**: 431–435.
133. Henriquez M, Armisen R, Stutzin A, Quest AF. Cell death by necrosis, a regulated way to go. *Curr Mol Med* 2008; **8**: 187–206.
134. Wu W, Liu P, Li J. Necroptosis: an emerging form of programmed cell death. *Crit Rev Oncol Hematol* 2012; **82**: 249–258.
135. Guerra S, Leri A, Wang X, Finato N, Di Loreto C, Beltrami CA *et al*. Myocyte death in the failing human heart is gender dependent. *Circ Res* 1999; **85**: 856–866.
136. Smith CC, Davidson SM, Lim SY, Simpkin JC, Hotherhall JS, Yellon DM. Necrostatin: a potentially novel cardioprotective agent? *Cardiovasc Drugs Ther* 2007; **21**: 227–233.
137. Bamber AR, Pryce J, Cook A, Ashworth M, Sebire NJ. Myocardial necrosis and infarction in newborns and infants. *Forensic Sci Med Pathol* 2013; **9**: 521–527.
138. Wang K, Liu F, Zhou LY, Ding SL, Long B, Liu CY *et al*. miR-874 regulates myocardial necrosis by targeting caspase-8. *Cell Death Dis* 2013; **4**: e709.
139. O'Donnell MA, Perez-Jimenez E, Oberst A, Ng A, Massoumi R, Xavier R *et al*. Caspase 8 inhibits programmed necrosis by processing CYLD. *Nat Cell Biol* 2011; **13**: 1437–1442.
140. Liu J, van Mil A, Vrijzen K, Zhao J, Gao L, Metz CH *et al*. MicroRNA-155 prevents necrotic cell death in human cardiomyocyte progenitor cells via targeting RIP1. *J Cell Mol Med* 2011; **15**: 1474–1482.
141. Zhang YY, Liu H. Connections between various trigger factors and the RIP1/RIP3 signaling pathway involved in necroptosis. *Asian Pac J Cancer Prev* 2013; **14**: 7069–7074.
142. Chiong M, Wang ZV, Pedrozo Z, Cao DJ, Troncoso R, Ibacache M *et al*. Cardiomyocyte death: mechanisms and translational implications. *Cell Death Dis* 2011; **2**: e244.
143. Smith CC, Yellon DM. Necroptosis, necrostatins and tissue injury. *J Cell Mol Med* 2011; **15**: 1797–1806.
144. Nakagawa T, Shimizu S, Watanabe T, Yamaguchi O, Otsu K, Yamagata H *et al*. Cyclophilin D-dependent mitochondrial permeability transition regulates some necrotic but not apoptotic cell death. *Nature* 2005; **434**: 652–658.
145. Frank SA. Evolution of robustness and cellular stochasticity of gene expression. *PLoS Biol* 2013; **11**: e1001578.
146. Giampieri E, Remondini D, de Oliveira L, Castellani G, Lio P. Stochastic analysis of a miRNA-protein toggle switch. *Mol Biosyst* 2011; **7**: 2796–2803.
147. Bostjancic E, Zidar N, Glavac D. MicroRNA microarray expression profiling in human myocardial infarction. *Dis Markers* 2009; **27**: 255–268.
148. Pan Z, Sun X, Ren J, Li X, Gao X, Lu C *et al*. miR-1 exacerbates cardiac ischemia-reperfusion injury in mouse models. *PLoS One* 2012; **7**: e50515.
149. Glass C, Singla DK. MicroRNA-1 transfected embryonic stem cells enhance cardiac myocyte differentiation and inhibit apoptosis by modulating the PTEN/Akt pathway in the infarcted heart. *Am J Physiol Heart Circ Physiol* 2011; **301**: H2038–H2049.
150. Tang Y, Zheng J, Sun Y, Wu Z, Liu Z, Huang G. MicroRNA-1 regulates cardiomyocyte apoptosis by targeting Bcl-2. *Int Heart J* 2009; **50**: 377–387.
151. Yu XY, Song YH, Geng YJ, Lin QX, Shan ZX, Lin SG *et al*. Glucose induces apoptosis of cardiomyocytes via microRNA-1 and IGF-1. *Biochem Biophys Res Commun* 2008; **376**: 548–552.
152. Shan H, Li X, Pan Z, Zhang L, Cai B, Zhang Y *et al*. Tanshinone IIA protects against sudden cardiac death induced by lethal arrhythmias via repression of microRNA-1. *Br J Pharmacol* 2009; **158**: 1227–1235.
153. Zhang Y, Zhang L, Chu W, Wang B, Zhang J, Zhao M *et al*. Tanshinone IIA inhibits miR-1 expression through p38 MAPK signal pathway in post-infarction rat cardiomyocytes. *Cell Physiol Biochem* 2010; **26**: 991–998.
154. Karakikes I, Chaanane AH, Kang S, Mukete BN, Jeong D, Zhang S *et al*. Therapeutic cardiac-targeted delivery of miR-1 reverses pressure overload-induced cardiac hypertrophy and attenuates pathological remodeling. *J Am Heart Assoc* 2013; **2**: e000078.
155. Xu C, Lu Y, Pan Z, Chu W, Luo X, Lin H *et al*. The muscle-specific microRNAs miR-1 and miR-133 produce opposing effects on apoptosis by targeting HSP60, HSP70 and caspase-9 in cardiomyocytes. *J Cell Sci* 2007; **120**(Pt 17): 3045–3052.
156. He B, Xiao J, Ren AJ, Zhang YF, Zhang H, Chen M *et al*. Role of miR-1 and miR-133a in myocardial ischemic postconditioning. *J Biomed Sci* 2011; **18**: 22.
157. Li C, Fang Z, Jiang T, Zhang Q, Liu C, Zhang C *et al*. Serum microRNAs profile from genome-wide serves as a fingerprint for diagnosis of acute myocardial infarction and angina pectoris. *BMC Med Genomics* 2013; **6**: 16.
158. Zhou X, Mao A, Wang X, Duan X, Yao Y, Zhang C. Urine and serum microRNA-1 as novel biomarkers for myocardial injury in open-heart surgeries with cardiopulmonary bypass. *PLoS One* 2013; **8**: e62245.
159. van Mil A, Vrijzen KR, Goumans MJ, Metz CH, Doevendans PA, Sluiter JP. MicroRNA-1 enhances the angiogenic differentiation of human cardiomyocyte progenitor cells. *J Mol Med (Berl)* 2013; **91**: 1001–1012.
160. Willimott S, Wagner SD. Post-transcriptional and post-translational regulation of Bcl2. *Biochem Soc Trans* 2010; **38**: 1571–1575.
161. Liu LF, Liang Z, Lv ZR, Liu XH, Bai J, Chen J *et al*. MicroRNA-15a/b are up-regulated in response to myocardial ischemia/reperfusion injury. *J Geriatr Cardiol* 2012; **9**: 28–32.

162. Hullinger TG, Montgomery RL, Seto AG, Dickinson BA, Semus HM, Lynch JM *et al*. Inhibition of miR-15 protects against cardiac ischemic injury. *Circ Res* 2012; **110**: 71–81.
163. Chamorro-Jorganes A, Araldi E, Penalba LO, Sandhu D, Fernandez-Hernando C, Suarez Y. MicroRNA-16 and microRNA-424 regulate cell-autonomous angiogenic functions in endothelial cells via targeting vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1. *Arterioscler Thromb Vasc Biol* 2011; **31**: 2595–2606.
164. Eitel I, Adams V, Dieterich P, Fuernau G, de Waha S, Desch S *et al*. Relation of circulating MicroRNA-133a concentrations with myocardial damage and clinical prognosis in ST-elevation myocardial infarction. *Am Heart J* 2012; **164**: 706–714.
165. Zhang L, Wu Y, Li Y, Xu C, Li X, Zhu D *et al*. Tanshinone IIA improves miR-133 expression through MAPK ERK1/2 pathway in hypoxic cardiac myocytes. *Cell Physiol Biochem* 2012; **30**: 843–852.
166. Danielson LS, Park DS, Rotllan N, Chamorro-Jorganes A, Gujjarro MV, Fernandez-Hernando C *et al*. Cardiovascular dysregulation of miR-17-92 causes a lethal hypertrophic cardiomyopathy and arrhythmogenesis. *FASEB J* 2013; **27**: 1460–1467.
167. van Almen GC, Verhesen W, van Leeuwen RE, van de Vrie M, Eurlings C, Schellings MW *et al*. MicroRNA-18 and microRNA-19 regulate CTGF and TSP-1 expression in age-related heart failure. *Aging Cell* 2011; **10**: 769–779.
168. Frank D, Gantenberg J, Boomgaarden I, Kuhn C, Will R, Jarr KU *et al*. MicroRNA-20a inhibits stress-induced cardiomyocyte apoptosis involving its novel target Egl3/PHD3. *J Mol Cell Cardiol* 2012; **52**: 711–717.
169. Qin DN, Qian L, Hu DL, Yu ZB, Han SP, Zhu C *et al*. Effects of miR-19b overexpression on proliferation, differentiation, apoptosis and Wnt/beta-catenin signaling pathway in P19 cell model of cardiac differentiation *in vitro*. *Cell Biochem Biophys* 2013; **66**: 709–722.
170. Qin Y, Yu Y, Dong H, Bian X, Guo X, Dong S. MicroRNA 21 inhibits left ventricular remodeling in the early phase of rat model with ischemia-reperfusion injury by suppressing cell apoptosis. *Int J Med Sci* 2012; **9**: 413–423.
171. Sayed D, He M, Hong C, Gao S, Rane S, Yang Z *et al*. MicroRNA-21 is a downstream effector of AKT that mediates its antiapoptotic effects via suppression of Fas ligand. *J Biol Chem* 2010; **285**: 20281–20290.
172. Cheng Y, Liu X, Zhang S, Lin Y, Yang J, Zhang C. MicroRNA-21 protects against the H<sub>2</sub>O<sub>2</sub>-induced injury on cardiac myocytes via its target gene PDCD4. *J Mol Cell Cardiol* 2009; **47**: 5–14.
173. Cheng Y, Zhu P, Yang J, Liu X, Dong S, Wang X *et al*. Ischaemic preconditioning-regulated miR-21 protects heart against ischaemia/reperfusion injury via anti-apoptosis through its target PDCD4. *Cardiovasc Res* 2010; **87**: 431–439.
174. Zeng J, Xiong Y, Li G, Liu M, He T, Tang Y *et al*. MiR-21 is overexpressed in response to high glucose and protects endothelial cells from apoptosis. *Exp Clin Endocrinol Diabetes* 2013; **121**: 425–430.
175. He J, Yue Y, Dong C, Xiong S. MiR-21 confers resistance against CVB3-induced myocarditis by inhibiting PDCD4-mediated apoptosis. *Clin Invest Med* 2013; **36**: E103–E111.
176. Kolpa HJ, Peal DS, Lynch SN, Giokas AC, Ghatak S, Misra S *et al*. miR-21 represses Pdc4 during cardiac valvulogenesis. *Development* 2013; **140**: 2172–2180.
177. Qian L, Van Laake LW, Huang Y, Liu S, Wendland MF, Srivastava D. miR-24 inhibits apoptosis and represses Bim in mouse cardiomyocytes. *J Exp Med* 2011; **208**: 549–560.
178. Li J, Donath S, Li Y, Qin D, Prabhakar BS, Li P. miR-30 regulates mitochondrial fission through targeting p53 and the dynamin-related protein-1 pathway. *PLoS Genet* 2010; **6**: e1000795.
179. Li X, Kong M, Jiang D, Qian J, Duan Q, Dong A. MicroRNA-150 aggravates H<sub>2</sub>O<sub>2</sub>-induced cardiac myocyte injury by down-regulating c-myc gene. *Acta Biochim Biophys Sin (Shanghai)* 2013; **45**: 734–741.
180. Mutharasan RK, Nagpal V, Ichikawa Y, Ardehali H. microRNA-210 is upregulated in hypoxic cardiomyocytes through Akt- and p53-dependent pathways and exerts cytoprotective effects. *Am J Physiol Heart Circ Physiol* 2011; **301**: H1519–H1530.
181. Rane S, He M, Sayed D, Vashistha H, Malhotra A, Sadoshima J *et al*. Downregulation of miR-199a derepresses hypoxia-inducible factor-1alpha and Sirtuin 1 and recapitulates hypoxia preconditioning in cardiac myocytes. *Circ Res* 2009; **104**: 879–886.
182. Ren XP, Wu J, Wang X, Sartor MA, Qian J, Jones K *et al*. MicroRNA-320 is involved in the regulation of cardiac ischemia/reperfusion injury by targeting heat-shock protein 20. *Circulation* 2009; **119**: 2357–2366.
183. Ding SL, Wang JX, Jiao JQ, Tu X, Wang Q, Liu F *et al*. A pre-microRNA-149 (miR-149) genetic variation affects miR-149 maturation and its ability to regulate the puma protein in apoptosis. *J Biol Chem* 2013; **288**: 26865–26877.
184. Wang JX, Jiao JQ, Li Q, Long B, Wang K, Liu JP *et al*. miR-499 regulates mitochondrial dynamics by targeting calcineurin and dynamin-related protein-1. *Nat Med* 2011; **17**: 71–78.
185. Lv G, Shao S, Dong H, Bian X, Yang X, Dong S. MicroRNA-214 protects cardiac myocytes against H<sub>2</sub>O<sub>2</sub>-induced injury. *J Cell Biochem* 2013.
186. Aurora AB, Mahmoud AI, Luo X, Johnson BA, van Rooij E, Matsuzaki S *et al*. MicroRNA-214 protects the mouse heart from ischemic injury by controlling Ca<sub>2</sub>(+) overload and cell death. *J Clin Invest* 2012; **122**: 1222–1232.
187. Fichtlscherer S, De Rosa S, Fox H, Schwietz T, Fischer A, Liebetrau C *et al*. Circulating microRNAs in patients with coronary artery disease. *Circ Res* 2010; **107**: 677–684.
188. Fang J, Song XW, Tian J, Chen HY, Li DF, Wang JF *et al*. Overexpression of microRNA-378 attenuates ischemia-induced apoptosis by inhibiting caspase-3 expression in cardiac myocytes. *Apoptosis* 2012; **17**: 410–423.
189. Zhu H, Yang Y, Wang Y, Li J, Schiller PW, Peng T. MicroRNA-195 promotes palmitate-induced apoptosis in cardiomyocytes by down-regulating Sirt1. *Cardiovasc Res* 2011; **92**: 75–84.
190. Tabuchi T, Satoh M, Itoh T, Nakamura M. MicroRNA-34a regulates the longevity-associated protein SIRT1 in coronary artery disease: effect of statins on SIRT1 and microRNA-34a expression. *Clin Sci (Lond)* 2012; **123**: 161–171.
191. Ito T, Yagi S, Yamakuchi M. MicroRNA-34a regulation of endothelial senescence. *Biochem Biophys Res Commun* 2010; **398**: 735–740.
192. Pan W, Zhong Y, Cheng C, Liu B, Wang L, Li A *et al*. MiR-30-regulated autophagy mediates angiotensin II-induced myocardial hypertrophy. *PLoS One* 2013; **8**: e53950.
193. Jian X, Xiao-yan Z, Bin H, Yu-feng Z, Bo K, Zhi-nong W *et al*. MiR-204 regulate cardiomyocyte autophagy induced by hypoxia-reoxygenation through LC3-II. *Int J Cardiol* 2011; **148**: 110–112.
194. Courboulin A, Paulin R, Giguere NJ, Saksouk N, Perreault T, Meloche J *et al*. Role for miR-204 in human pulmonary arterial hypertension. *J Exp Med* 2011; **208**: 535–548.
195. Xiao J, Zhu X, He B, Zhang Y, Kang B, Wang Z *et al*. MiR-204 regulates cardiomyocyte autophagy induced by ischemia-reperfusion through LC3-II. *J Biomed Sci* 2011; **18**: 35.
196. Ucar A, Gupta SK, Fiedler J, Erikci E, Kardasinski M, Batkai S *et al*. The miRNA-212/132 family regulates both cardiac hypertrophy and cardiomyocyte autophagy. *Nat Commun* 2012; **3**: 1078.
197. Seca H, Lima RT, Lopes-Rodrigues V, Guimaraes JE, Almeida GM, Vasconcelos MH. Targeting miR-21 induces autophagy and chemosensitivity of leukemia cells. *Curr Drug Targets* 2013; **14**: 1135–1143.



**Cell Death and Disease** is an open-access journal published by Nature Publishing Group. This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by-nc-nd/3.0/>